Rituximab for anti-vimentin antibody diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether rituximab, a medication that calms the immune system, can help people with certain nerve or brain conditions linked to a specific antibody. It aims to reduce symptoms or prevent the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tested positive for anti-vimentin antibodies in your spinal fluid.
- Your condition has caused moderate to severe disability (score of 3.5 or higher on a scale from 0 to 10).
- You have had signs of disease activity in the last 6 months, such as new brain or spinal lesions, worsening symptoms, or a relapse.
- You are willing to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This phase 1 trial tests whether rituximab (a drug that targets certain immune cells) can help reduce side effects caused by immunotherapy. The goal is to find a safe dose and see if it improves symptoms without harming your cancer treatment.
This study tests whether a medication called rituximab can help people with psychotic symptoms that are linked to an autoimmune response (when the immune system attacks the brain). If you or your child have these antibodies, this treatment might reduce symptoms.
Hear when a new Anti-Vimentin Antibody-associated Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.